Cathepsin K - Pipeline Review, H2 2019
Cathepsin K - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Cathepsin K - Pipeline Review, H2 2019'; Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) pipeline Target constitutes close to 5 molecules.
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.
The report 'Cathepsin K - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Bone Cancer, Chagas Disease (American Trypanosomiasis), Neuropathic Pain (Neuralgia) and Osteoarthritis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Cathepsin K - Pipeline Review, H2 2019'; Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) pipeline Target constitutes close to 5 molecules.
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.
The report 'Cathepsin K - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Bone Cancer, Chagas Disease (American Trypanosomiasis), Neuropathic Pain (Neuralgia) and Osteoarthritis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
- The report reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
Evotec SE
Mateon Therapeutics Inc
Medivir AB
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
KGP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIV-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
Featured News & Press Releases
May 06, 2019: Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress
Apr 30, 2019: Data from the MIV-711 phase II program to be presented at the OARSI World Congress
Oct 19, 2018: New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21
Jul 27, 2018: MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
Jun 28, 2018: Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study
Apr 26, 2018: Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27
Nov 09, 2017: MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology
Oct 24, 2017: Medivir Receives FDA Fast Track Designation for MIV-711 for the Treatment of OA
Oct 20, 2017: MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology
Sep 25, 2017: Medivir announces Positive Topline Results from phase IIA osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure
Sep 14, 2017: Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study
Aug 16, 2017: FDA accepts Medivir?s IND application for MIV-711, enabling clinical development in the US
Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications
Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
Evotec SE
Mateon Therapeutics Inc
Medivir AB
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
KGP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIV-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
Featured News & Press Releases
May 06, 2019: Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress
Apr 30, 2019: Data from the MIV-711 phase II program to be presented at the OARSI World Congress
Oct 19, 2018: New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21
Jul 27, 2018: MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
Jun 28, 2018: Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study
Apr 26, 2018: Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27
Nov 09, 2017: MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology
Oct 24, 2017: Medivir Receives FDA Fast Track Designation for MIV-711 for the Treatment of OA
Oct 20, 2017: MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology
Sep 25, 2017: Medivir announces Positive Topline Results from phase IIA osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure
Sep 14, 2017: Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study
Aug 16, 2017: FDA accepts Medivir?s IND application for MIV-711, enabling clinical development in the US
Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications
Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by Mateon Therapeutics Inc, H2 2019
Pipeline by Medivir AB, H2 2019
Pipeline by Virobay Inc, H2 2019
Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by Mateon Therapeutics Inc, H2 2019
Pipeline by Medivir AB, H2 2019
Pipeline by Virobay Inc, H2 2019
Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
COMPANIES MENTIONED
Evotec SE
Mateon Therapeutics Inc
Medivir AB
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
COMPANIES MENTIONED
Evotec SE
Mateon Therapeutics Inc
Medivir AB
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
